Johnson & Johnson completes $20bn takeover of Synthes
19 June 2012
Johnson & Johnson has completed the acquisition of Synthes,
Inc. for a total purchase price of $19.7 billion in cash and stock.
Synthes has been integrated with the DePuy franchise to establish
the DePuy Synthes Companies of Johnson & Johnson.
"The completion of the Synthes acquisition creates the world's most
innovative and comprehensive orthopaedics business and reflects our
long-standing strategy of leadership within attractive healthcare
markets," said Alex Gorsky, Chief Executive Officer, Johnson &
Johnson. "The combination of these two respected leaders — Synthes
and DePuy — will enable us to better serve clinicians and patients
worldwide, bring new innovations to the marketplace in orthopaedics
and neurologics, and strengthen our ability to compete in developing
"This is a very exciting day for the people of Synthes and DePuy as
we become one comprehensive enterprise dedicated to advancing
patient care through innovative, total solutions that are developed
from a deep understanding of our customers' needs," said Michel
Orsinger, Worldwide Chairman, Global Orthopaedics Group, and former
CEO of Synthes. "We are building on the legacy and strengths of two
great companies to create one organization that will be agile and
responsive in today's evolving health care environment."